Articles by Tyler Menichiello

  1. Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells 9/26/2023

    Coeptis Therapeutics' new CSO, Dr. Colleen Delaney, explains why she thinks umbilical cord blood is the best source of starting material for allogeneic cell therapies.

  2. Excision BioTherapeutics' CSO Discusses Dual-Guide RNA's Impact On Gene Editing 9/15/2023

    Excision BioTherapeutics' CSO, Dr. TJ Cradick, explains Excision's dual-guide RNA approach to cure chronic, viral infectious diseases.

  3. Challenges Stunting The AAV Field 9/7/2023

    DeciBio conducted a survey among leaders in the AAV vector space to identify key pain points in the field. Dr. Carl Schoellhammer discusses these results and what they mean for the industry moving forward.

  4. Considerations For Licensing Platforms From Universities 6/16/2023

    Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.